ALKS 2680 Shows Promise for Narcolepsy Type 1, Reducing Sleepiness and Cataplexy

Narcolepsy Type 1 is a chronic neurological condition characterized by overwhelming daytime sleepiness and cataplexy (sudden loss of muscle tone triggered by strong emotions). It significantly impacts quality of life due to unpredictable sleep attacks and muscle weakness. Current treatments often manage symptoms but don't address the underlying mechanisms effectively. This Phase 2 study aimed to evaluate the safety and efficacy of ALKS 2680 in reducing sleepiness and cataplexy in Narcolepsy Type 1 patients.

The study demonstrated a dose-dependent improvement in wakefulness and a significant reduction in cataplexy with ALKS 2680. At Week 6, the 8 mg dose group showed the most substantial improvement, with an average increase in MSL of 12.5 minutes from baseline, compared to only 2.1 minutes in the placebo group (p<0.001). The 6 mg group also showed a significant increase of 9.8 minutes (p<0.01), and the 4 mg group an increase of 6.2 minutes (p<0.05). The 8 mg dose of ALKS 2680 led to a 43% reduction in weekly cataplexy attacks compared to baseline, significantly outperforming placebo which saw only a 5% reduction (p<0.001). Overall, ALKS 2680 was well-tolerated across all doses, with no serious adverse events reported, and the most common side effects being mild headache and nausea, occurring in less than 10% of participants. These findings suggest a robust therapeutic effect on both primary symptoms of Narcolepsy Type 1.